mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

por Le Tourneau, C, Faivre, S, Serova, M, Raymond, E
Publicado 2008

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity

por Serova, M, Bieche, I, Sablin, M-P, Pronk, G J, Vidaud, M, Cvitkovic, E, Faivre, S, Raymond, E
Publicado 2011

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma

por Santos, C D, Tijeras-Raballand, A, Serova, M, Sebbagh, S, Slimane, K, Faivre, S, de Gramont, A, Raymond, E
Publicado 2015

Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells

por Serova, M, Galmarini, C M, Ghoul, A, Benhadji, K, Green, S R, Chiao, J, Faivre, S, Cvitkovic, E, Le Tourneau, C, Calvo, F, Raymond, E
Publicado 2007

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells

por Benhadji, K A, Serova, M, Ghoul, A, Cvitkovic, E, Le Tourneau, C, Ogbourne, S M, Lokiec, F, Calvo, F, Hammel, P, Faivre, S, Raymond, E
Publicado 2008